TransCode Therapeutics(RNAZ) - 2025 FY - Earnings Call Transcript

Financial Data and Key Metrics Changes - The meeting discussed the election of directors and the approval of an amendment to the stock option plan, which included an increase of 166,724 shares available for issuance [4][7] - The appointment of Witham Smith and Brown P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified [7][8] Business Line Data and Key Metrics Changes - No specific financial data or metrics related to individual business lines were provided during the meeting [10] Market Data and Key Metrics Changes - No specific market data or metrics were discussed in the meeting [10] Company Strategy and Development Direction - The company is focused on advancing its Phase I clinical trial, which includes a wide range of tumor types [10] - Future announcements regarding specific results from the clinical trial are expected in September [11] Management's Comments on Operating Environment and Future Outlook - Management indicated that the trial is an all-comers clinical trial, allowing participation from patients with various solid tumors [10] - There is an ongoing interest in the company's clinical studies, with a total of 16 patients treated in the Phase I trial [11] Other Important Information - The meeting concluded with the acknowledgment of shareholder interest and the adjournment of the Annual Meeting of Stockholders [12] Q&A Session Summary Question: How many patients are currently undergoing Transcode clinical studies? How many have dropped out and for what reasons? Are there patients with demonstrated tumor regressions so far? - The company reported that a total of 16 patients have been treated in the Phase I clinical trial, with more details expected to be announced in September [10][11]